BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22512880)

  • 1. [Hepatic encephalopathy and liver transplantation].
    Fehérvári I; Nemes B; Görög D; Gerlei Z; Kóbori L
    Magy Seb; 2012 Apr; 65(2):58-62. PubMed ID: 22512880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic encephalopathy: pathophysiology and emerging therapies.
    Sundaram V; Shaikh OS
    Med Clin North Am; 2009 Jul; 93(4):819-36, vii. PubMed ID: 19577116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides.
    Morgan MY
    Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut flora and hepatic encephalopathy in patients with cirrhosis.
    Riordan SM; Williams R
    N Engl J Med; 2010 Mar; 362(12):1140-2. PubMed ID: 20335591
    [No Abstract]   [Full Text] [Related]  

  • 7. Disaccharides in the treatment of hepatic encephalopathy.
    Sharma P; Sharma BC
    Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
    Maev IV; V'iuchnova ES; Lebedeva EG; Iakovenko EI; Dicheva DT
    Klin Med (Mosk); 2002; 80(5):42-5. PubMed ID: 12087887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy.
    Patil DH; Westaby D; Mahida YR; Palmer KR; Rees R; Clark ML; Dawson AM; Silk DB
    Gut; 1987 Mar; 28(3):255-9. PubMed ID: 3570029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Hepatic Encephalopathy: A Primer.
    Jawaro T; Yang A; Dixit D; Bridgeman MB
    Ann Pharmacother; 2016 Jul; 50(7):569-77. PubMed ID: 27126547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rifaximin in the treatment of hepatic encephalopathy].
    Lata J; Hůlek P; Fejfar T; Spicák J; Drastich P; Marecek Z; Brůha R; Husová L; Senkyrík M
    Vnitr Lek; 2002 Jun; 48(6):578-82. PubMed ID: 12132365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
    Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Overt Hepatic Encephalopathy.
    Sussman NL
    Clin Liver Dis; 2015 Aug; 19(3):551-63. PubMed ID: 26195208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.
    Zhu GQ; Shi KQ; Huang S; Wang LR; Lin YQ; Huang GQ; Chen YP; Braddock M; Zheng MH
    Aliment Pharmacol Ther; 2015 Apr; 41(7):624-35. PubMed ID: 25684317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials.
    Als-Nielsen B; Gluud LL; Gluud C
    BMJ; 2004 May; 328(7447):1046. PubMed ID: 15054035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial.
    Elkington SG; Floch MH; Conn HO
    N Engl J Med; 1969 Aug; 281(8):408-12. PubMed ID: 4894464
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic liver diseases. Hepatic encephalopathy too frequently overlooked?].
    MMW Fortschr Med; 2000 Jun; 142(25):56-7. PubMed ID: 10920673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.